What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
His main research concerns Internal medicine, Myocardial infarction, Stroke, Randomized controlled trial and Surgery.
His biological study spans a wide range of topics, including Placebo, Endocrinology and Cardiology.
His work deals with themes such as Epidemiology, Heart failure and Emergency medicine, which intersect with Myocardial infarction.
His Stroke research focuses on subjects like Atrial fibrillation, which are linked to Heart rate.
His study in Randomized controlled trial is interdisciplinary in nature, drawing from both Anesthesia and Confidence interval.
His Surgery study combines topics from a wide range of disciplines, such as Warfarin and Risk factor.
His most cited work include:
- Apixaban versus Warfarin in Patients with Atrial Fibrillation (5705 citations)
- Apixaban in Patients with Atrial Fibrillation (1891 citations)
- Predictors of hospital mortality in the global registry of acute coronary events. (1578 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Stroke, Myocardial infarction and Epidemiology.
His research on Internal medicine frequently connects to adjacent areas such as Surgery.
In general Cardiology, his work in ST elevation, Coronary artery disease and Ejection fraction is often linked to In patient linking many areas of study.
As a part of the same scientific family, Alvaro Avezum mostly works in the field of Stroke, focusing on Aspirin and, on occasion, Rivaroxaban.
His Myocardial infarction study incorporates themes from Odds ratio and Risk factor.
His Epidemiology research is multidisciplinary, relying on both Gerontology, Environmental health, Diabetes mellitus, Disease and Prospective cohort study.
He most often published in these fields:
- Internal medicine (51.99%)
- Cardiology (28.48%)
- Stroke (24.83%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (51.99%)
- Epidemiology (16.56%)
- Randomized controlled trial (15.56%)
In recent papers he was focusing on the following fields of study:
Alvaro Avezum mainly focuses on Internal medicine, Epidemiology, Randomized controlled trial, Stroke and Prospective cohort study.
The Internal medicine study combines topics in areas such as Placebo and Cardiology.
He has researched Epidemiology in several fields, including Diabetes mellitus, Cohort study, Family medicine and Environmental health.
His study in the fields of Clinical endpoint under the domain of Randomized controlled trial overlaps with other disciplines such as Hydroxychloroquine.
Alvaro Avezum has included themes like Renal function, Heart failure, Atrial fibrillation and Risk factor in his Stroke study.
The various areas that Alvaro Avezum examines in his Prospective cohort study study include Incidence, Blood lipids, Disease, Vascular disease and Cohort.
Between 2018 and 2021, his most popular works were:
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (593 citations)
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. (383 citations)
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. (227 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
